 |
市場調查報告書
商品編碼
1667183
腫瘤學市場機會、成長動力、產業趨勢分析與 2025 - 2034 年預測Oncology Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
||||||
2024 年全球腫瘤市場規模達到 3,203 億美元，預計 2025 年至 2034 年的複合年成長率為 10.8%。腫瘤學研究的進展旨在揭示癌症的根本原因和發展，推動創新治療方法的發展並改善患者的治療效果。
市場分為癌症診斷和癌症治療。癌症診斷包括影像、活體組織切片、腫瘤生物標記測試、液體活體組織切片、免疫組織化學和原位雜合技術。同時，癌症治療領域涵蓋化療、標靶治療、免疫治療、荷爾蒙治療和其他干預措施。 2024 年，由於全球癌症負擔不斷增加，癌症治療領域將佔據最大的市場佔有率，達到 54.6%。這種成長歸因於人口老化、生活方式的改變和環境因素。吸菸、不良飲食、缺乏運動和接觸污染物是導致全球癌症發生率上升的主要原因。
| 市場範圍 | |
|---|---|
| 起始年份 | 2024 |
| 預測年份 | 2025-2034 |
| 起始值 | 3203億美元 |
| 預測值 | 8661億美元 |
| 複合年成長率 | 10.8％ |
市場根據癌症類型進一步分類，包括乳癌、肺癌、攝護腺癌、大腸癌、胃癌、肝癌、食道癌和其他癌症。其中，乳癌仍然是收入領先的領域，這得益於其發病率不斷上升以及對早期發現和治療進步的日益關注。造成這現象的因素包括遺傳傾向、人口老化以及生活方式的轉變。對癌症研究和醫療保健基礎設施的大量投資，特別是在新興市場，進一步改善了獲得先進診斷和治療的機會。這些努力正在加速市場成長並加強全球患者護理。
隨著癌症發生率的上升，美國腫瘤學市場可望大幅成長。人口老化和生活方式風險等因素對醫療保健系統提出了更高的要求，推動了對先進治療和診斷技術的需求。癌症負擔日益加重，促使製藥公司、醫院和研究機構創新並開發更有效的治療方法、診斷方法和支援服務。
目錄
第 1 章：方法論與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業衝擊力
- 成長動力
- 全球癌症發生率上升
- 政府和其他組織採取多項措施傳播疾病意識
- 發展中國家診斷實驗室數量不斷增加
- 已開發國家的技術進步
- 產業陷阱與挑戰
- 診斷影像系統相關資本投入高，成本高
- 癌症治療相關的副作用風險和 CT 掃描儀相關風險較高
- 缺乏技術精湛、訓練有素的腫瘤科醫生和放射科醫生
- 成長動力
- 成長潛力分析
- 監管格局
- 技術格局
- 未來市場趨勢
- 差距分析
- 波特的分析
- PESTEL 分析
第4章：競爭格局
- 介紹
- 公司市佔率分析
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 策略儀表板
第 5 章：市場估計與預測：按癌症診斷與治療，2021 年 - 2034 年
- 主要趨勢
- 癌症診斷
- 腫瘤生物標記檢測
- 影像學
- 活體組織切片
- 液體活體組織切片
- 免疫組織化學
- 原位雜合技術
- 癌症治療
- 化療
- 標靶治療
- 免疫療法
- 荷爾蒙治療
- 其他癌症治療
第 6 章：市場估計與預測：按癌症類型，2021 年至 2034 年
- 主要趨勢
- 肺癌
- 攝護腺癌
- 結腸和直腸癌
- 胃癌
- 食道癌
- 肝癌
- 乳癌
- 其他癌症類型
第 7 章：市場估計與預測：依最終用途，2021 年至 2034 年
- 主要趨勢
- 醫院
- 診斷實驗室
- 診斷影像中心
- 學術界
- 專科診所
- 其他最終用途
第 8 章：市場估計與預測：按地區，2021 年至 2034 年
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 波蘭
- 瑞士
- 荷蘭
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- 泰國
- 印尼
- 越南
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 哥倫比亞
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 以色列
第9章：公司簡介
- AbbVie
- Amgen
- AstraZeneca
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- GE HealthCare Technologies
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck & Co
- Novartis
- Pfizer
- F. Hoffmann-La Roche
- Sanofi
- Takeda Pharmaceutical Company Limited
The Global Oncology Market reached USD 320.3 billion in 2024 and is projected to grow at a CAGR of 10.8% from 2025 to 2034. Oncology, as a medical specialty, focuses on preventing, diagnosing, and treating cancer through a wide array of strategies, including surgical procedures, chemotherapy, radiotherapy, targeted therapies, and immunotherapy. Advances in oncology research aim to uncover the underlying causes and progression of cancer, driving the development of innovative treatments and improving patient outcomes.
The market is divided into cancer diagnostics and cancer treatment. Cancer diagnostics include imaging, biopsies, tumor biomarker tests, liquid biopsies, immunohistochemistry, and in situ hybridization. Meanwhile, the cancer treatment segment covers chemotherapy, targeted therapies, immunotherapy, hormonal therapy, and other interventions. In 2024, the cancer treatment segment held the largest market share at 54.6%, supported by a rising global cancer burden. This increase is attributed to aging populations, changing lifestyles, and environmental factors. Smoking, poor diets, physical inactivity, and exposure to pollutants are key contributors to the increasing incidence of cancer worldwide.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $320.3 Billion |
| Forecast Value | $866.1 Billion |
| CAGR | 10.8% |
The market is further categorized by cancer type, including breast, lung, prostate, colorectal, gastric, liver, esophageal, and other cancers. Among these, breast cancer remains a leading segment in terms of revenue, fueled by its rising prevalence and growing focus on early detection and treatment advancements. Contributing factors include genetic predisposition, aging demographics, and shifting lifestyle patterns. Substantial investments in cancer research and healthcare infrastructure, particularly in emerging markets, are further improving access to advanced diagnostics and therapies. These efforts are accelerating market growth and enhancing patient care globally.
U.S. oncology market is poised for substantial growth, driven by the rising incidence of cancer cases. Factors such as an aging population and lifestyle risks are placing significant demands on healthcare systems, fueling the need for advanced treatments and diagnostic technologies. The growing burden of cancer is encouraging pharmaceutical companies, hospitals, and research institutions to innovate and develop more effective therapies, diagnostics, and support services.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 3600 Synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising incidence of cancer globally
- 3.2.1.2 Several initiatives undertaken by government and other organizations to spread disease awareness
- 3.2.1.3 Growing number of diagnostic laboratories in developing countries
- 3.2.1.4 Technological advancements in developed countries
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High capital investment coupled with high cost associated with diagnostic imaging system
- 3.2.2.2 High risk of side effects associated with cancer treatment and risks associated with CT scanners
- 3.2.2.3 Dearth of well-skilled and trained oncologists and radiologists
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.6 Future market trends
- 3.7 Gap analysis
- 3.8 Porter’s analysis
- 3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Cancer Diagnostics and Treatment, 2021 – 2034 ($ Mn)
- 5.1 Key trends
- 5.2 Cancer diagnostics
- 5.2.1 Tumor biomarkers test
- 5.2.2 Imaging
- 5.2.3 Biopsy
- 5.2.4 Liquid biopsy
- 5.2.5 Immunohistochemistry
- 5.2.6 In situ hybridization
- 5.3 Cancer treatment
- 5.3.1 Chemotherapy
- 5.3.2 Targeted therapy
- 5.3.3 Immunotherapy
- 5.3.4 Hormonal therapy
- 5.3.5 Other cancer treatments
Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 – 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Lung cancer
- 6.3 Prostate cancer
- 6.4 Colon and rectal cancer
- 6.5 Gastric cancer
- 6.6 Esophageal cancer
- 6.7 Liver cancer
- 6.8 Breast cancer
- 6.9 Other cancer types
Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)
- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Diagnostic laboratories
- 7.4 Diagnostic imaging centers
- 7.5 Academia
- 7.6 Specialty clinics
- 7.7 Other end use
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Poland
- 8.3.7 Switzerland
- 8.3.8 Netherlands
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 India
- 8.4.3 Japan
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Thailand
- 8.4.7 Indonesia
- 8.4.8 Vietnam
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Colombia
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Israel
Chapter 9 Company Profiles
- 9.1 AbbVie
- 9.2 Amgen
- 9.3 AstraZeneca
- 9.4 Bristol-Myers Squibb Company
- 9.5 Eli Lilly and Company
- 9.6 GE HealthCare Technologies
- 9.7 Gilead Sciences
- 9.8 GlaxoSmithKline
- 9.9 Johnson & Johnson
- 9.10 Merck & Co
- 9.11 Novartis
- 9.12 Pfizer
- 9.13 F. Hoffmann-La Roche
- 9.14 Sanofi
- 9.15 Takeda Pharmaceutical Company Limited
